THAILAND

Potential Impact of Takeda’s Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results

Published on 24/05/2021

» •Takeda’s dengue vaccine candidate (TAK-003) prevented 83.6% of hospitalizations and 62.0% of dengue illness overall, with no identified important safety risks through three years following vaccination in ongoing pivotal Phase 3 TIDES trial • Regulatory filings for TAK-003 progressing in European Union and in many dengue-endemic countries; filing in United States planned for later this year • Dengue is the fastest-spreading mosquito-borne viral disease with an estimated 390 million cases and 500,000 hospitalizations per year globally, with limited options for prevention